Great West Life Assurance Co. Can Reduces Position in Inogen, Inc. (NASDAQ:INGN)


Share on StockTwits

Great West Life Assurance Co. Can cut its position in Inogen, Inc. (NASDAQ:INGN) by 9.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,115 shares of the medical technology company’s stock after selling 2,085 shares during the period. Great West Life Assurance Co. Can owned 0.10% of Inogen worth $612,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Voloridge Investment Management LLC grew its position in shares of Inogen by 126.2% in the 3rd quarter. Voloridge Investment Management LLC now owns 45,309 shares of the medical technology company’s stock valued at $1,314,000 after buying an additional 25,281 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Inogen in the 3rd quarter valued at $685,000. Squarepoint Ops LLC purchased a new position in shares of Inogen in the 3rd quarter valued at $272,000. State of Tennessee Treasury Department grew its position in shares of Inogen by 40.0% in the 3rd quarter. State of Tennessee Treasury Department now owns 12,991 shares of the medical technology company’s stock valued at $376,000 after buying an additional 3,710 shares during the last quarter. Finally, Weld Capital Management LLC purchased a new position in shares of Inogen in the 3rd quarter valued at $349,000. 98.00% of the stock is currently owned by hedge funds and other institutional investors.

INGN stock opened at $46.60 on Thursday. Inogen, Inc. has a one year low of $26.57 and a one year high of $55.55. The stock has a market capitalization of $1.03 billion, a PE ratio of -517.72 and a beta of 0.98. The company has a fifty day moving average of $41.63 and a 200-day moving average of $33.88.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Wednesday, November 4th. The medical technology company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.06). Inogen had a negative net margin of 0.66% and a positive return on equity of 0.21%. The company had revenue of $74.30 million during the quarter, compared to analyst estimates of $76.06 million. During the same quarter last year, the business earned $0.31 EPS. The firm’s revenue for the quarter was down 19.1% on a year-over-year basis. Equities research analysts forecast that Inogen, Inc. will post -0.31 earnings per share for the current year.

In other Inogen news, CFO Alison Bauerlein sold 8,702 shares of the firm’s stock in a transaction dated Tuesday, December 15th. The shares were sold at an average price of $40.16, for a total transaction of $349,472.32. Following the completion of the transaction, the chief financial officer now directly owns 11,017 shares in the company, valued at approximately $442,442.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Brenton Taylor sold 11,017 shares of the firm’s stock in a transaction dated Friday, January 8th. The shares were sold at an average price of $46.72, for a total transaction of $514,714.24. Following the transaction, the executive vice president now owns 67,609 shares of the company’s stock, valued at $3,158,692.48. The disclosure for this sale can be found here. 4.83% of the stock is owned by company insiders.

INGN has been the topic of a number of recent analyst reports. KeyCorp raised shares of Inogen from a “sector weight” rating to an “overweight” rating and set a $60.00 target price on the stock in a research report on Monday, December 14th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research note on Friday, November 13th. BidaskClub upgraded shares of Inogen from a “hold” rating to a “buy” rating in a research note on Friday, December 25th. Finally, ValuEngine cut shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 5th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $49.80.

Inogen Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Recommended Story: Profit Margin

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.